9361 documents

Read All
00:06 , Nov 17, 2018 |  BC Extra  |  Company News

Novartis joins call asking FDA to stop biosimilar trash-talkers

Novartis AG (NYSE:NVS; SIX:NOVN) joined Pfizer Inc. (NYSE:PFE) in asking FDA to stop campaigns from branded drugmakers that the pharmas say are misleading the public about the safety of biosimilars. Novartis submitted its comments in...
Read More
22:54 , Nov 16, 2018 |  BC Extra  |  Company News

Pfizer to increase list price of 41 drugs

Pfizer Inc. (NYSE:PFE) said it plans to increase the list price for 41 medicines, effective Jan. 15. Last month, Chairman and CEO Ian Read said the pharma will likely end its agreement to defer drug...
Read More
20:42 , Nov 16, 2018 |  BC Extra  |  Clinical News

Imfinzi fails again in MYSTIC trial for first-line NSCLC

In another strike against tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination with PD-L1 inhibitor Imfinzi durvalumab missed the co-primary endpoint of improving overall survival (OS) in the Phase III MYSTIC trial...
Read More
18:04 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

uniQure hemophilia B gene therapy leads to Factor IX activity level of 31% of normal

uniQure N.V. (NASDAQ:QURE) reported that all three patients who received hemophilia B gene therapy AMT-061 in a dose-confirmation Phase IIb trial achieved and sustained therapeutic levels of Factor IX activity. The company has started enrollment...
Read More
17:37 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Pfizer launches U.S.’s first biosimilar epoetin

Pfizer Inc. (NYSE:PFE) launched the first biosimilar of anemia drug epoetin alfa in the U.S., priced at a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen and Johnson...
Read More
17:28 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Eidos' AG10 leads to >90% TTR stabilization at day 28 in Phase II

Eidos Therapeutics Inc. (NASDAQ:EIDX) said AG10 led to >90% stabilization of transthyretin (TTR) at day 28 in all treated patients in a Phase II trial to treat symptomatic TTR amyloid cardiomyopathy. Twice-daily AG10 significantly increased...
Read More
16:10 , Nov 16, 2018 |  BC Week In Review  |  Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Nov. 14 decision that invalidated second medical use patent...
Read More
16:03 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Concert's hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reported Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE). Twice-daily 8 mg...
Read More
16:02 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Sangamo delays readout for hemophilia A gene therapy

Sangamo Therapeutics Inc. (NASDAQ:SGMO) said on its 3Q18 earnings call on Nov. 8 that it will not submit a late-breaking abstract to present Phase I/II data for its hemophilia A gene therapy at next month's...
Read More
15:55 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

NextCure Inc. (Beltsville, Md.) raised $93 million on Nov. 13 in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates. PD-1...
Read More